MOLOGIC
The science and technology to transform rapid diagnostics
Media Enquiries
Mologic is currently working on the development of a rapid diagnostic test for COVID-19.
Please visit the News section of our website for the latest updates around this work.
For media enquiries related to this and our other work:
Whether you’re at the start of your journey with a great rapid point-of-care diagnostic idea, or need to scale up manufacturing, we have the expertise, creativity and resources you need. We’re the lateral flow pioneer and the partner you’re looking for at any, or every stage of development.
Mologic. We’re with you every step of the way.
Capabilities
RESEARCH & DEVELOPMENT
Partnering with Mologic gives you access to our world-leading scientific team, and the expertise gained from a wealth of contract projects and internal programmes.
Our team combines a broad range of skills and is experienced in developing human, animal and agricultural assays.
Capabilities
ANTIBODY DEVELOPMENT
You know what you want your immunoassay to achieve, and we can help develop the right antibodies to help you get there – improving performance, reducing cost and saving time.
Mologic offers a polyclonal, monoclonal and recombinant monoclonal development service, using the latest molecular engineering techniques to create novel binding molecules (bi-specific, fragments and more)
Capabilities
PROTEIN DEVELOPMENT
Mologic provides high quality, recombinant protein expression services for protein and antibody production and contract manufacturing for diagnostic devices.
Whatever stage you’re at with your project, you can access our services, from initial feasibility studies, to scaling up production of diagnostic devices using your target protein.
Capabilities
MANUFACTURING
If you have a device or reagent ready to go, but need help starting or scaling up manufacture, look no further.
Mologic has the skills and capabilities to get your product off the ground, with a custom solution that allows for cost-effective, low to mid volume manufacturing.
EXPERIENCED
We have proven expertise in technical problem-solving and deliver commercially successful products, including inflammation biomarkers, protease enzymology, biorecognition and the creation of novel technology.
RESPECTED
We were chosen by the Bill & Melinda Gates Foundation to develop new, ultra-sensitive technology platforms with a focus on delivering easy-to-use point-of-care diagnostics with low manufacturing costs.
CONNECTED
We offer vast IVD experience and an international network built on successful project delivery. We promise cutting-edge performance in all areas of product development and manufacture.
SEAMLESS
We can take products through every phase of the development cycle, or step in at any stage if you have particular requirements, or don’t have the specific expertise in house.
INNOVATIVE
We have ten patent families granted in the US and EU on enabling technology, with patents in process on new innovations including enzyme activity detection and respiratory disease algorithms.
TRUSTED
We have partnered with some of the world’s most respected industrial, pharmaceutical and healthcare brands, successfully completing over 75 contract research projects to date.
“40 years ago my quest, with my colleagues, was for a new PoC immunoassay technique that combined unparalleled simplicity with sensitivity, speed and specificity. During the next 10 years we created, patented and commercialised the lateral flow platform (the Clearblue® pregnancy test) – job done!But 1980s technology can’t meet today’s demands for increased simplicity and super-sensitivity for low-abundance biomarkers. In Mologic, we are now closing that gap in LF performance through innovations in antibody engineering, fine particles, smart chemistry and more. The journey continues! ”
Latest News
Mologic’s COVID-19 Rapid Antigen Self-Test Selected by NIH for RADx Initiative Funding
Supported by US initiative to accelerate development and manufacturing [...]
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test
York and Bedfordshire, UK, 17 March 2021: Aptamer Group, [...]
Avacta and Mologic announce commercial partnership
Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid [...]